Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Mankind Pharma Ltd.
Change Company   
BSE Code 543904
ISIN Demat INE634S01028
Book Value 334.22
NSE Code MANKIND
Dividend Yield % 0.00
Market Cap 1156610.67
P/E 57.03
EPS 49.15
Face Value 1  
20-Dec-2024 Mankind Pharma informs about updates
03-Dec-2024 Appointment of Director
15-Nov-2024 Mankind Pharma informs about disclosure
06-Nov-2024 Mankind Pharma informs about newspaper publicati...
25-Oct-2024 Mankind Pharma submits intimation of board meetin...
24-Oct-2024 Mankind Pharma completes transaction to acquire 1...
16-Oct-2024 Mankind Pharma informs about allotment of non-con...
17-Sep-2024 Allotment of Equity Shares
04-Sep-2024 Mankind Pharma to transfer OTC business undertaki...
20-Aug-2024 Mankind Pharma informs about presentation
14-Aug-2024 Mankind Pharma informs about allotment under ESOP
07-Aug-2024 Mankind Pharma informs about investors meet
31-Jul-2024 Mankind Pharma’s Q1FY25 consolidated net profit s...
26-Jul-2024 Mankind Pharma inks pact to acquire 100% stake in...
26-Jul-2024 Mankind Pharma informs about change in time of co...
Page 1 of 2
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.